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Helicobacter pylori is a Gram-negative motile bacterium causative agent of
acute and chronic digestive and extra-digestive human infections. According to
different reports worldwide, H. pylori symptomatic and asymptomatic infections are
a global problem. The statistical investigations show a percentage of 50 for people
who are involved in H. pylori acute/chronic digestive and/or extra-digestive infections
around the world. This review focuses on digestive and extra-digestive diseases caused
by H. pylori, the related virulence factors, diagnostic techniques including non-
invasive and invasive diagnostics and treatment. There is an abundance of diagnostics
for detection and identiﬁcation of H. pylori. The availability, cost, and the condition of
test performance may differ from place to place. To increase the level of reliability in
association with diagnostic tools for detecting H. pylori, several techniques must be
applied at once as multi-diagnostic technique. Furthermore, there are several phar-
macotherapies which can be used for complete eradication of H. pylori infection.
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Introduction
Helicobacter pylori is a curved motile Gram-negative spiral bacterium,
which has been isolated from gastritis patients by Australian scientists Marshall
andWarren in 1983. The unipolar ﬂagellum makes the bacterium highly motile for
quick movements and attachments to gastric mucosa. According to some studies,
H. pylori is naturally able to colonize on the surface of gastroduodenal mucosa of
human beings, a relationship with a background of near 60,000 years old [1–11].
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H. pylori is an important bacterial infectious agent that causes signiﬁcant
gastrointestinal tract (GIT) and extra-digestive infections worldwide. Infections
caused by H. pylori are more frequent in overcrowded populations with low
hygiene [3, 4, 12, 13].
The recorded reports from different countries show that approximately 50%
of people are infected byH. pylori around the world. The coverage system relating
to high urease activity enables H. pylori to survive in acidic condition of stomach.
The powerful ureolytic activity of cytoplasmic urease produced by H. pylori
catalyses the conversion of gastric juice urea into alkaline ammonia and carbon
dioxide which is produced in stomach [5–7, 14–22].
The majority of patients with H. pylori GIT infections have no signiﬁcant
clinical gastric involvement and sometimes there are asymptomatic patients.
However, chronic gastric inﬂammation or gastritis is the predominant clinical
symptom in association withH. pylori digestive infections and it is known as a risk
factor in patients with GIT diseases including gastric mucosa in association with
lymphoid tissue (MALT) lymphoma, gastric cancer (GC) and adenocarcinoma,
gastroesophageal reﬂux disease, and duodenal ulcers (DU). Complete eradication
of H. pylori by antibiotics may lead to deﬁnitive treatment of early MALT
lymphoma. Previous studies indicate a close association between infections
caused by H. pylori and GC [5, 6, 19, 21, 23–32].
Mostly, people acquire digestive and extra-digestive H. pylori infections in
their childhood and without any antibiotic therapy they may be carried in an
individual’s whole life [29].
There are many extra-digestive diseases and infections including autoim-
mune diseases, bronchiectasis, cardiovascular diseases, colonic and pancreatic
diseases, diabetes mellitus, hepatobiliary system diseases, neurological diseases,
skin diseases, and hematological diseases that are in association with H. pylori
(Table I) [13, 30, 32–42].
In the present review, we show the digestive and extra-digestive infections
and diseases caused by H. pylori, the related virulence factors, diagnostic
techniques including non-invasive and invasive diagnostics and treatment.
Virulence Factors in Digestive and Extra-digestive Pathogenic Strains of
H. pylori
Adhesion is the most important factor for colonization of microorganisms.
In consequence, colonization of microbial populations including H. pylori may
lead to translocation of virulence factors from pathogen into host cell and
facilitate the persistence of infection. Thus there are several genes that play
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important role as virulence factors in different pathogenic strains of H. pylori
(Table II) [21, 30, 43–52].
Genetic studies have corroborated the presence of cag pathogenicity island
(cag PAI) in the pathogenic strains of H. pylori. The cag PAI is a 40,000 bp
chromosomal DNA segment which is made up of 31 genes and divided into cag I
and cag II [21, 30, 47, 53–55].
The pathogenic strains of H. pylori causing digestive and extra-digestive
diseases encompass cag PAI. Therefore, H. pylori bacteria are divided into two
groups of cagA-positive and cagA-negative strains. The cagE has intensive
correlation with cagA and both genes contribute in digestive and extra-digestive
diseases [21, 30, 56–61].
The vacA gene is detected in all strains of H. pylori and three alleles
including s (signal), i (intermediate), and m (middle) are recognized for it. The
vacA gene is responsible for longevity of H. pylori infection [21, 30, 47–50, 61].
The dupA, the DU promoting gene placed in malleability part of the genome
of H. pylori is known as a bipartite sequence consisted of two genes of jhp0917
and jhp0918.
The iceA gene is induced by contact with epithelium possesses the allelic
variants of iceA1 and iceA2. The iceA1 and nlaIIIR (a gene detected in Neisseria
lactamica encoding a type of restricted enzyme which act in CTAG speciﬁc
sequence) genes have an ambient homology with each other. The activity of iceA2
is unknown [30, 61].
The bab alleles involving babA1, babA2, and babB are known as blood group
antigen binding genes. The babA2may be expressed with cagA and vacA genes and
among its alleles, e.g., babA1 and babB have a key role in pathogenesis [30, 62].
Table I. Extra-digestive diseases and their subgroups caused by H. pylori
Extra-digestive group
diseases Subgroups of diseases
Autoimmune diseases Autoimmune thyroid disease (ATD), Grave’s disease, rheumatoid arthritis,
Crohn’s disease, Behcet’s disease
Cardiovascular diseases Atherosclerotic plaques, ischemic heart disease, Coronary artery disease,
stroke
Colonic and pancreatic
diseases
Colorectal cancer, colorectal adenoma, colorectal adenocarcinoma, GC
Hepatobiliary system
diseases
Non-alcoholic fatty liver disease, cirrhosis, hepatic encephalopathy, liver
ﬁbrosis, hepatocellular carcinoma, cholangiocarcinoma
Neurological diseases Dementia, Alzheimer disease, multiple sclerosis, neuromyelitis optica
Skin diseases Chronic urticaria, chronic facial dermatosis (rosacea), psoriasis vulgaris,
Henoch–Schönlein purpura, alopecia areata, Sweet’s syndrome
Hematological diseases Iron deﬁciency anemia, pan gastritis, idiopathic thrombocytopenic purpura
(ITP)
DIAGNOSTICS AND TREATMENT OF H. PYLORI INFECTION 275
Acta Microbiologica et Immunologica Hungarica 64, 2017
The sabA, a sialic acid binding adhesion gene has an effective role in
adherence of H. pylori to the host cells [30].
The oipA, the gene of outer inﬂammatory protein has a strong correlation
with other virulent genes including cagA, iceA, and vacA. oipA is an active gene in
H. pylori pathogenesis [30].
Table II. The relationship between virulence factor genes, their functions, and phenotypic manifestations
Genes Protein Properties Function
Phenotypic
manifestations
cagA CagA Oncoprotein Formation of bacterial
type IV secretion system,
Triggering
IL-6 production
Gastric inﬂammation-
associated diseases
(GIAD), peptic ulcer
diseases (PUD), GC,
cardiovascular
disease, ATD, ITP,
hepatobiliary system
diseases, colonic and
pancreatic diseases
cagE CagE Cytokine inducer Triggering IL-1β and
IL-8 production
PUD, hepatobiliary
system diseases
vacA VacA Vacuolating
cytotoxin
Epithelial cell vacuolation,
induction of channels in
cell membrane, release
of mitochondrial
cytochrome c,
suppressing T-cell
responses
GIAD, PUD, GC,
hepatobiliary system
diseases
dupA DupA Duodenal ulcer
promoting gene
Formation of bacterial
type IV secretion system,
triggering IL-8
production
GC, dyspepsia, PUD
such as DU
iceA
(iceA1,
iceA2)
IceA Producing via
bacterial contact
with gastric
epithelial cells
Triggering IL-8
production
Asymptomatic gastritis,
dyspepsia, PUD such
as DU, GC,
hepatobiliary system
diseases
bab
(babA1,
babA2,
babB)
BabA1,
BabA2,
BabB
Adhesin Binding activity to
blood group antigens
(H. pylori tropism
mechanism)
PUD such as DU,
intestinal metaplasia,
hepatobiliary system
diseases, GC
sabA SabA Adhesin Binding to sialylated
glycans on the surface of
host epithelial and red
blood cells, inducing
phagocytosis
GIAD, GC
oipA OipA/
HopH
Pro-inﬂammatory
outer membrane
protein
Triggering IL-8
production
GIAD, PUD such as DU
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The sextette genes including babA, babB, hopZ, oipA, sabA, and sabB
encode for the outer membrane proteins that are closely correlated with gastrodu-
odenal lesions and infections via bacterial adhesion. The aforementioned genes are
variable in different strains of H. pylori [21, 43, 63–65].
Furthermore, enzymes including catalase, lipase, phospholipase, protease,
and urease are inﬂuent virulence factors in the pathogenesis of H. pylori
strains [38].
In addition to H. pylori virulence factors, there are several genetic factors in
human hosts that predispose the digestive and extra-digestive infections and
diseases (Table III).
Moreover, the environmental predisposing factors including salt, vinegar,
alcohol, and smoke trigger the progression of GC [12, 13, 30, 34, 59, 66, 67].
Diagnostic Techniques
There are several available diagnostic procedures which are categorized into
two major groups of non-invasive (without endoscopy) and invasive (with
endoscopy) tests. The aforementioned tests are used for detecting digestive and
extra-digestive infections and diseases caused by pathogenic strains of H. pylori;
however, the non-invasive tests are more usual for diagnosing extra-digestive
diseases [38, 68–72].
All of the tests including non-invasive and invasive are reliable and accurate,
but each one has its limitations. Thus, there is a huge lack of single test as Gold
Standard and optimal diagnostic technique. The only way to increase reliability of
diagnosis is to apply for a multi-diagnostic tool [70, 73–75].
According to recent studies, for improving diagnostic tests and managing
treatments, all individuals with DU disease must be checked via clinical tests
before antibiotic therapy. Testing program is a proper strategy for diagnosing and
Table III. The relationship among host predisposing factor, type of predisposing factor, and phenotypic
demonstration
Host predisposing factors Type of predisposing factor Phenotypic demonstration
Gene polymorphism Polymorphic antagonist genes of
interleukin-1β (IL-1β) and IL-1
receptors
Raising the progression of
GC up to 2–3 times
Polymorphic regulator genes of tumor
necrosis factor-α and IL-8, IL-16
Raising the progression of
GC signiﬁcantly
Polymorphic receptors belonging to the
innate immune system
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managing H. pylori infection [68, 76–79]. In a day-to-day routine diagnostic
method for H. pylori infection, there are some factors including sensitivity,
speciﬁcity, experience level of experts, stage of diagnosis (pre-treatment or
post-treatment stages), technical availability, and costs which are considered to
employ a particular test [70, 71, 80].
Non-invasive diagnostic tests
Non-invasive assays or non-endoscopic tests are more acceptable and
pleasant to individuals; because these tests are cheaper and more comfort and
safer in compare with invasive or endoscopic methods. Furthermore, non-invasive
techniques are often known as the best choice in epidemiological investigations.
Totally, non-endoscopic techniques are recommended for most of the patients with
particular situation such as children, pregnant women, and others with any risky
condition are recommended for non-invasive diagnostic tools [70, 81–83].
Non-invasive tests are categorized into two main groups of direct and
indirect techniques. Stool assay is a direct non-invasive test in which the presence
of bacterial antigens is directly evaluated. The assessment of the presence of
antibodies or other elements like CO2 due to H. pylori infection is classiﬁed as
indirect non-invasive techniques including 13C-urea breath test (UBT). The most
common non-invasive screening settings of H. pylori infection involve UBT and
serologic assays. In addition, other reliable tests including stool assay and
commercial diagnostic kits are available. However, there are some advantages
and disadvantages with each one of the mentioned tools [68, 71, 74, 82].
Non-invasive indirect tests
Ureolytic-based tests
13C-urea breath technique. UBT as a direct non-invasive test with diagnostic
accuracy of >95% (sensitivity >95%, speciﬁcity >95%) is easy to perform and
based on urea hydrolysis achieving within gastric mucosal epithelial cells
produces ammonia and CO2. In this test, when an individual with H. pylori
infection ingests 13C-labeled urea, H. pylori as a famous urease enzyme producer
breaks down the urea and the labeled CO2 will be monitored within a short time. It
takes 2 h for collecting the breath samples of patients. Also, a single sample is
collectible in 40 min by the help of hyamine as a CO2 trapping agent for exhaling
into it. Finally, the percentage of radioactivity of each sample is calculated by a
scintillation counter. 13C has a non-radioactive property; so, the test is safe for
children and pregnant women. UBT is occurred in different manners such as meal-
based 13C UBT, tablet-based 13C UBT, and 14C UBT. Recently, the tablet-based
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13C UBT is recommended. Different reports conﬁrm UBT as an accessible,
accurate, safe, and practical test [70, 73, 83–87].
Serum bicarbonate and ammonia vapor tests. In addition to UBT, there are
other ureolytic techniques including serum bicarbonate and ammonia vapor which
have their special applications. In serum bicarbonate test, the measure of serum
13C-carbonate is evaluated. This test is reliable and suitable as post-treatment
setting.
Ammonia vapor test is used for assessing the level of ammonia gas in the
patient breath. This method is absolutely cost effective method [71–88].
Immunologic techniques
Serological tests. Serological tests are divided into four formats including the
enzyme-linked immunosorbent assay (ELISA), agglutination, western blotting,
and immunochromatography [70, 71, 89].
Serological tests regarding H. pylori infection diagnosis are designed for
detecting speciﬁc antibodies such as anti-H. pylori IgG antibodies or anti-CagA
and anti-VacA antibodies. In adults, the preferable sample is serum, while in
children is saliva or urine. Serologic diagnostic tools are cheap with high
limitations. However, the serological tests are common and accessible in a wide
range. Depending on the type of serological tests, their sensitivity is up to
90%–97% and the speciﬁcity of them varies from 50% to 96%. Thus, each
serological test must be used in validated settings. Some of the serological
commercial kits are suitable and available [68, 70, 71, 73, 90].
Serological tests are not capable to distinguish active infection from
previous contact. Today, serological tests are the third common techniques
between non-invasive tools for diagnosing H. pylori infection. According to
previous reports, the use of combined serological methods may increase the
sensitivity and the speciﬁcity of the tests [70, 71, 73, 90, 91].
Salivary and urinary tests. For decreasing the stressful condition of vene-
puncture in children, serum test is replaced by saliva or urine tests in children. In
comparison with sera samples, the results of salivary antibody assays demonstrat-
ed inappropriate sensitivity and speciﬁcity; but it seems that the use of special
applicators as beneﬁcial device increases the sensitivity and the speciﬁcity of the
tests [70, 71, 92–95]. Some reports show the preference of urine assay with higher
sensitivity and speciﬁcity [71, 96, 97].
Near-patient assays. The near-patient assays seem to be an on-site and fast
technique with low sensitivity and speciﬁcity. Totally, the accuracy of near patient
assays is low. The ﬁnal results vary depending on the condition of whole blood.
The whole blood taken from capillary system show different results (sensitivity
and speciﬁcity) than the venous whole blood because of their various components’
DIAGNOSTICS AND TREATMENT OF H. PYLORI INFECTION 279
Acta Microbiologica et Immunologica Hungarica 64, 2017
concentrations. Therefore, the near-patient assays are not recommended when the
laboratory-based tests are available [70, 71].
Non-invasive direct tests
Stool antigen test (SAT). The SAT or fecal antigen test (FAT) is known as rapid,
simple, and facilitated technique which is based on fecal antigen detection of
H. pylori. In new format of the SAT or FAT, polyclonal antibodies are replaced
by monoclonal antibodies. The SAT or FAT is divided into two forms of
laboratory tests (e.g., ELISA with high accuracy) and speedy in-ofﬁce tests
(e.g., immunochromatographic method with limited accuracy). According to
previous reports, the sensitivity as well as the speciﬁcity of the SAT or the FAT
is ~95%. The SAT or the FAT assays are useful for pre-treatment and
posttreatment diagnosis of H. pylori infection. The SAT or the FAT tests are
improved the level of diagnostics of H. pylori infection. Among non-invasive
diagnostic techniques, for pre-treatment diagnosis of H. pylori infection, the
UBT and the SAT (FAT) tests have the same value in accuracy; but for
posttreatment diagnosis of H. pylori infection, the UBT is the ﬁrst choice and
the SAT (FAT) is the second one [4, 68, 70, 71, 86, 98–102].
Invasive diagnostic tests
Invasive tests or endoscopic techniques based on biopsy (histology), culture,
rapid urease test (RUT), molecular biology, e.g., polymerase chain reaction (PCR)
are used for detecting H. pylori infection, worldwide. The situation of patients
determines the type of invasive tests. An appropriate specimen raises the accuracy
of the test [5, 70, 83, 86].
Urease-based assays. Urease tests such as RUT are rapid, cheap with proper
accuracy but they have to be validated for different groups of the patients.
H. pylori is a typical bacterium, which produces a huge amount of urease enzymes.
The biopsy specimen is laid into a buffer free urea solution with a pH indicator of
phenol red. The presence of H. pylori in the biopsy may lead to conversion of urea
into ammonia and carbon dioxide which in consequence, the pH raises up and the
color of solution start to change. The sensitivity of RUT is ∼95% and the
speciﬁcity depending on its performance varies from 85% to 95% [4, 5, 68, 70].
Histologic-based assays. Histologic techniques indicate a proper evidence of
illustrated information through providing sections from gastric mucosa infected by
H. pylori. The presence of H. pylori is distinguished via typical curved appearance
of the microorganism on the gastric epithelial cells. The biopsy specimens are
stained by different stains including Warthin–Starry silver stain, Giemsa, Genta,
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alcian yellow-toluidine blue, immunochemical stains, and hematoxylin and eosin.
The Giemsa stain is more common and it has a sensitivity of 90%. Genta’s stain
gives a qualiﬁed illustration of H. pylori and the tissue. The alcian yellow-
toluidine blue is a proper stain with the same sensitivity as Giemsa stain. But the
former is cheap, facilitated, and gives qualiﬁed contrast.
Immunochemical stains with monoclonal antibodies increase the speciﬁcity
of the histologic tests [5, 70, 103–105].
It is important to know that the speciﬁcity of histologic-based tests is >95%
while the sensitivity of these tests relying on quality of the biopsy, location of
biopsy, size of the biopsy, frequency of the biopsy, and the applied staining varies
from 50% to 95% [68, 70].
Culture-based assays and antimicrobial susceptibility tests. In the most cases,
culture tests are used for antibiotic therapy and their applications for clinical
diagnostics are rare. Biopsies containing H. pylori must be cultured in the minimum
time; because H. pylori is very sensitive to environmental factors. The Stuart’s
transport medium is a suitable choice to recover the bacteria within 24 h at 4 °C.
Mostly biopsies are used for culture media, but oral or fecal specimens may be used
rarely. The culture medium of Brain Heart Infusion Agar base comprising blood,
starch, charcoal, and bovine serum albumin is used for culture-based tests [68, 70, 86].
The culture-based tests are mainly used for sensitivity testing of H. pylori.
The antimicrobial susceptibility tests reveal suitable antibiotics for infection
treatment and show the pharmacological resistances. An accurate test may lead
to a deﬁnite and proper treatment. The common antibiotics which are used for
treatment involve amoxicillin, clarithromycin, metronidazole, and tetracycline.
Some resistant strains are reported for metronidazole and clarithromycin. Depend-
ing on the number of biopsies, culture medium, transport style, and methodology,
the sensitivity of culture-based assays varies from 50% to 95% while the
speciﬁcity of these techniques is >95% [68, 70, 86, 106].
Molecular biology tests. Molecular biology techniques have a vast range of
application from diagnosing to typing. Also, samples may be taken either from
cultures or from specimens. Different types of molecular techniques including
in situ hybridization, PCR, multiplex-PCR, real-time PCR and DNA microarray
can be used in clinical diagnostics. The sensitivity and the speciﬁcity of molecular
tools are >95%. Molecular biology tests are often used for identiﬁcation of
antibiotic resistant strains. Among aforementioned molecular diagnostics, DNA
microarray is an advanced accurate and rapid diagnostic technique which can be
used when there are a huge number of clinical samples. DNA microarray is a
powerful technique for detection and identiﬁcation of drug-resistant and suscepti-
ble microbial strains. However, this technique is expensive when the number of
clinical specimens is low [70, 86, 107–116].
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Fluorescent in situ hybridization (FISH). FISH is an accurate, rapid, reliable,
sensitive, and speciﬁc molecular diagnostic method based on targeting the
H. pylori 16S rRNA and 23S rRNA genes by ﬂuorescein-labeled oligonucleotide
probes. According to previous investigations, FISH is an advanced diagnostic
technique with high sensitivity (97%) and speciﬁcity (94%). Furthermore, this
method is able to recognize antimicrobial resistant bacteria and in particular
clarithromycin-resistant strains of H. pylori. The recognition of clarithromycin-
resistant and clarithromycin-susceptible strains of H. pylori takes only 3 h.
However, FISH costs expensive and is not suitable for children and young adults.
Until now PCR techniques and in particular real-time PCR are routine clinical
methods for detection and identiﬁcation of drug-resistant and susceptible strains of
H. pylori; moreover, real-time PCR is easy to achieve, rapid, with high sensitivity
(98%) and speciﬁcity (92%). It is also a cost effective technique [117–124].
In recent years, a new developed technique has raised up which is based on
FISH and can be performed in the form of in vivo. The method of ﬂuorescence
in vivo hybridization (FIVH) is a combined technique consisted of confocal laser
microscopy, FISH, and histopathological assays. The preference of this diagnostic
technique is the ability of direct observation of live ﬂuorescent H. pylori cells as
motile and non-motile bacterial cells within mucosal tissues and gastric epithelial
cells, respectively. The real time technique of FIVH is an appropriate diagnostic
tool for detecting and identifying different type of bacterial cells including
H. pylori. There are some limitations for utilizing FIVH as a routine clinical
diagnostic tool. Using special parts of the body, the level of pH, the need of
confocal laser endomicroscope, and high costs are important limitations for
application of FIVH as a routine clinical method. However, there is promising
future for FIVH by omitting the aforementioned limitations [121, 125, 126].
Treatment of H. pylori Infection
There are several pharmaceutical regimens which are used for treating
digestive and extra-digestive H. pylori infections and diseases. Rapid and accurate
diagnosis has an important role for treatment and eradication ofH. pylori. Because
of particular localization of H. pylori in gastric mucus layer, there is a need of
effective pharmacotherapy. The drugs must be penetrated into gastric mucosal
layer to prevent colonization of H. pylori. Therefore, monotherapy is not a good
choice for complete eradication of H. pylori. Even dual therapy is not sharp
effective. Mostly, triple treatment including two antimicrobial agents (antibiotics)
with a proton-pump inhibitor (PPI) (antisecretory agent) or a bismuth salt is
administered. However, quadruple therapy in which two antibiotics, combined
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with a PPI and a bismuth salt is sometimes a suitable alternative for complete
treatment ofH. pylori infection. There are some antibiotics such as clarithromycin,
tetracycline, metronidazole, and amoxicillin that have acceptable pure rate for
eradication of H. pylori. Metronidazole is a proper replacement for amoxicillin in
patients that have penicillin allergy. The role of PPIs is to block the H+, K+
ATPase pump and the bismuth salts have lytic effect onH. pylori by disrupting the
bacterial cell wall. The effects of dual, triple, and quadruple therapies are 70%,
85%, and 66.7%, respectively. Besides, the side effects of quadruple therapy are
more than the other therapies. However, it is an alternative for treatment-resistant
strains of H. pylori which cause to triple therapy failure [4, 5, 38, 86, 127, 128].
In accordance with a wide range of studies, the prevalence of drug-resistant
strains of H. pylori is clearly different from a region to another geographic area.
But the results indicate a remarkable increase in association with drug resistance
rate in many countries. Among a diversity of antibiotics, a signiﬁcant increase of
resistance rate against clarithromycin, levoﬂoxacin, moxiﬂoxacin, and metroni-
dazole has been recognized between H. pylori strains. Some reports show the
incredible increase of clarithromycin and metronidazole resistance rates up to
80%. On the other hand, the tetracycline and amoxicillin resistance rates are low
and insigniﬁcant in the majority of geographic areas, but not in Africa. These
reports emphasize the increase of pharmacotherapy failures which is related to
high general usage of antibiotics around the world. As the drug resistance rates
vary from a country to another, a local pharmacotherapy may be a good solution
for decreasing the rate of antimicrobial resistance among the strains of H. pylori
[122, 129–133].
Conclusion
H. pylori is one of the most important bacteria which may lead to different
forms of acute and chronic digestive and extra-digestive infections and diseases.
There are several virulence factors that support the level of bacterial pathogenicity.
Simultaneously, risk factors in susceptible people may accelerate the progression
of H. pylori infection. It is important that people with gastrointestinal disorders
with or without extra-digestive diseases must be checked and be controlled with
intervals.
Always the practical prophylactic health care is the ﬁrst choice in the ﬁeld of
infectious diseases. Rapid and accurate diagnostics are absolutely determinant
factors to control and treat the infection in early stages.
There are various invasive and non-invasive diagnostic methods for detect-
ing H. pylori infections and diseases.
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Among non-invasive assays UBT and SAT (FAT) are ﬁrst-line diagnostic
approaches and the serological tests have the low accuracy. However, the
availability, cost, and the condition of test performance may differ from place
to place. Thus, to improve the diagnostic methods there is no choice rather than
combination of two or more techniques with each other.
There are a number of pharmacotherapies, depending on the condition of
infections and diseases. Preferably, triple therapy is an appropriate choice but in
the presence of drug-resistant strains, quadruple therapy is recommended.
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